Autobio Diagnostics Hits Day Low of CNY 31.75 Amid Price Pressure

Autobio Diagnostics Co., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 4.15% to reach an intraday low of CNY 31.75. This performance stands in contrast to the China Shanghai Composite, which saw a modest decrease of 0.27% on the same day. Over the past week, Autobio Diagnostics has faced a 2.52% decline, while its monthly performance reflects a decrease of 4.09%. The stock has struggled significantly over the past year, with a loss of 17.7%, and a year-to-date performance showing a decline of 9.29%. The long-term outlook is similarly challenging, with a staggering 42.81% drop over the last three years and a 63.9% decline over the past five years. Key financial metrics indicate that the company has faced difficulties, with net sales growing at an annual rate of only 8.33% and operating profit at 3.45% over the last five years. The current market capitalization stands at CNY 19,693 million, with a price-to-earnings ratio of 18.00 and a dividend yield of 3.75%.